The correlation between bone biomarkers, glucosylsphingosine levels, and molecular findings in Gaucher type 1 patients under enzyme therapy
Author:
Ersoy Melike1ORCID, Yegül Duygu2ORCID, Pişkinpaşa Hamide3ORCID, Gedikbasi Asuman4ORCID
Affiliation:
1. Department of Pediatric Metabolism Disease , Istanbul Bakirkoy Dr Sadi Konuk Training and Research Hospital , Istanbul , Turkey 2. Department of Radiology , Istanbul Bakirkoy Dr Sadi Konuk Training and Research Hospital , Istanbul , Turkey 3. Department of Internal Medicine , Division of Endocrinology and Metabolism, Istanbul Bakirkoy Dr Sadi Konuk Training and Research Hospital , Istanbul , Turkey 4. Department of Pediatric Basic Sciences , Division of Medical Genetics, Istanbul University Istanbul Faculty of Medicine , Istanbul , Turkey
Abstract
Abstract
Objectives
We aimed to determine the relationship of Lyso-Gb1 levels, bone biomarkers, and mutation findings with bone marrow burden (BMB) scores.
Methods
Lyso-Gb1 and bone biomarkers, and BMB scores of 10 Gaucher type 1 (GD1) patients under enzyme therapy were prospectively evaluated.
Results
Ten GD1 patients, aged between 4.5 and 40 (mean 23 ± 11 years), were included in the study. Four patients were homozygous for L444P/L444P, and six patients were compound heterozygous for N370S/R415H. We found positive correlations between pain and BMB scores with Lyso-Gb1 levels (r=0.889, p=0.001 and r=0.701, p=0.035, respectively). There were negative correlations between bone mineral density (BMD) of both the lumbar spine and femoral neck between Lyso-Gb1 levels (r=−0.929, p=0.001 and r=−0.893, p=0.007, respectively). Patients with L444P/L444P mutation had higher Lyso-Gb1 levels and BMB, pain scores and lower BMD measurements than patients with N370S/R415H (p=0.01, p=0.02, p=0.03, p=0.04, p=0.04, respectively).
Conclusions
There was an apparent correlation between, Lyso-Gb1 levels, BMB scores and genotype in evaluating bone involvement in Gaucher patients.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,Molecular Biology,Biochemistry
Reference40 articles.
1. Stirnemann, J, Belmatoug, N, Camou, F, Serratrice, C, Froissart, R, Caillaud, C, et al.. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017;18:441. https://doi.org/10.3390/ijms18020441. 2. Aerts, JMFG, Kuo, CL, Lelieveld, LT, Boer, DEC, van der Lienden, MJC, Overkleeft, HS, et al.. Glycosphingolipids and lysosomal storage disorders as illustrated by Gaucher disease. Curr Opin Chem Biol 2019;53:204–15. https://doi.org/10.1016/j.cbpa.2019.10.006. 3. Zimran, A, Kay, A, Gelbart, T, Garver, P, Thurston, D, Saven, A, et al.. Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients. Medicine 1992;71:337–53. https://doi.org/10.1097/00005792-199211000-00002. 4. Weinreb, NJ, Charrow, J, Andersson, HC, Kaplan, P, Kolodny, EH, Mistry, P, et al.. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112–9. https://doi.org/10.1016/s0002-9343(02)01150-6. 5. Weinreb, N, Barranger, J, Packman, S, Prakash-Cheng, A, Rosenbloom, B, Sims, K, et al.. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007;71:576–88. https://doi.org/10.1111/j.1399-0004.2007.00811.x.
|
|